SENSEX
NIFTY 50
Hang Seng
Taiwan Weighted
MCX GOLD FEB 05
MCX SILVER MAR 05
USD/INR
EUR/INR80.0630

SENSEX
NIFTY 50
NIFTY MIDCAP 100
S&P BSE MIDCAP
Hang Seng
Taiwan Weighted
DAX
Nasdaq
MCX GOLD FEB 05
MCX SILVER MAR 05
MCX CRUDEOIL FEB 19
MCX NATURALGAS JAN 25
USD/INR
EUR/INR
GBP/INR
JPY/INR

Stock Market Live: Sensex slips over 700 points, Nifty falls below 14,400 dragged by metals, banks

Global Markets: Asia shares pare losses as China economy rebounds

Oil prices extend gains after US inventory drop

Wrapping 2020 with a subtle depreciation- What’s on the cards for the Rupee in 2021?

Auto

Vehicle bookings jump 100% in festive season, says Tata Motors

Updated : November 06, 2020 06:18 PM IST

The vehicle bookings have jumped as much as 100 percent in the festive season, said Shailesh Chandra, the President of the passenger vehicle (PV) business of Tata Motors in conversation with CNBC-TV18.

He also said that the share of pent-up demand has decreased and the shift to personal mobility is driving demand.

The vehicle bookings have jumped as much as 100 percent in the festive season, said Shailesh Chandra, the President of the passenger vehicle (PV) business of Tata Motors in conversation with CNBC-TV18.

He also said that the share of pent-up demand has decreased and the shift to personal mobility is driving demand.

“It has been overwhelming to see the response that we have in the festive season this year. In the Navaratri we saw a jump of more than 100 percent as far as bookings are concerned compared to last year’s Navaratri,” he said.

“Similar kind of jump we saw in retail also which was to the tune of 90 percent. This continued throughout October and Navaratri was definitely the time when bookings, as well as retails, had peaked. It clearly shows that there is great excitement among the consumers to buy cars in this festive season and the festive season is still not over. We have the next 14 days,” he further said.

"Retail sales of Tata Motors would be 15 percent more compared to the wholesale dispatches in October," he added.

You May Also Like

Bharat Biotech's Covaxin led to 'enhanced immune responses' in phase 1 trials, says Lancet

Bharat Biotech's Covaxin led to 'enhanced immune responses' in phase 1 trials, says Lancet

Phase 1 trial results show Covaxin has tolerable safety, enhanced immunity: Lancet study

Phase 1 trial results show Covaxin has tolerable safety, enhanced immunity: Lancet study

Closing Bell: Sensex ends 746 points lower, Nifty down 1.5%; banking, metal sectors drag most

Closing Bell: Sensex ends 746 points lower, Nifty down 1.5%; banking, metal sectors drag most

Trending on CNBC-TV18

Live TV

recommended for you